NeuroOne Medical Files 8-K

TL;DR

NeuroOne filed an 8-K on 8/15/25, but it's light on details.

AI Summary

NeuroOne Medical Technologies Corp. filed an 8-K on August 15, 2025, reporting on other events and financial statements/exhibits. The filing does not contain specific financial figures or details about the nature of the 'Other Events' beyond its classification.

Why It Matters

This 8-K filing indicates that NeuroOne Medical Technologies Corporation has made a regulatory submission, but it lacks specific details on the events or financial information disclosed.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without immediate disclosure of significant financial or operational changes.

Key Players & Entities

• NeuroOne Medical Technologies Corp. (company) — Registrant
• August 15, 2025 (date) — Date of Earliest Event Reported
• Delaware (jurisdiction) — State of Incorporation
• Eden Prairie, MN (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share NMTC The Nasdaq Stock Mar
• $6.75 million — ectus") for the offer and sale of up to $6.75 million of Shares through JonesTrading pursuant

Filing Documents

• ea0253334-8k_neuroone.htm (8-K) — 24KB
• ea025333401ex5-1_neuroone.htm (EX-5.1) — 13KB
• ex5-1_001.jpg (GRAPHIC) — 5KB
• 0001213900-25-077511.txt ( ) — 208KB
• nmtc-20250815.xsd (EX-101.SCH) — 3KB
• nmtc-20250815_lab.xml (EX-101.LAB) — 33KB
• nmtc-20250815_pre.xml (EX-101.PRE) — 22KB
• ea0253334-8k_neuroone_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On December 21, 2022, NeuroOne Medical Technologies Corporation (the "Company") entered into a Capital on Demand Sales Agreement (the "Sales Agreement") with JonesTrading Institutional Services LLC ("JonesTrading") pursuant to which the Company may sell from time to time shares of its common stock, par value $0.001 (the "Shares") through any method permitted that is deemed an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, under which JonesTrading will act as sales agent (the "ATM Program"). On August 15, 2025, the Company filed an updated Prospectus Supplement (the "Prospectus") for the offer and sale of up to $6.75 million of Shares through JonesTrading pursuant to the Sales Agreement. Honigman LLP, counsel to the Company, has issued an opinion relating to the Shares. A copy of such legal opinion is attached as Exhibit 5.1 hereto. The Shares will be sold pursuant to the Registration Statement, and offerings of the Shares will be made only by means of the Prospectus. This Current Report on Form 8-K shall not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state or jurisdiction

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Honigman LLP 104 Cover Page Interactive Data File (embedded in Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROONE MEDICAL TECHNOLOGIES CORPORATION Dated: August 15, 2025 By: /s/ David Rosa David Rosa Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR